lncRNA MALAT1 Regulates the Resistance of Breast Cancer Cells to Paclitaxel Via the miR-497-5p/ SHOC2 axis

References

• Ferlay J , ColombetM, SoerjomataramIet al. Cancer statistics for the year 2020: an overview. Int. J. Cancer doi:10.1002/ijc.33588 (2021) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Liu HM , MaLL, LiCet al. The molecular mechanism of chronic stress affecting the occurrence and development of breast cancer and potential drug therapy. Transl. Oncol.15(1), 101281 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang T , ZhouH, WangKet al. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed. Pharmacother.147, 112616 (2022).
   PubMed Web of Science ®Google Scholar
• Guo YJ , PanWW, LiuSB, ShenZF, XuY, HuLL. ERK/MAPK signalling pathway and tumorigenesis. Exp. Ther. Med.19(3), 1997–2007 (2020).
   PubMed Web of Science ®Google Scholar
• Lavoie H , GagnonJ, TherrienM. ERK signalling: a master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol.21(10), 607–632 (2020).
   PubMed Web of Science ®Google Scholar
• Stuart DD , SellersWR. Targeting RAF–MEK–ERK kinase–scaffold interactions in cancer. Nat. Med.19(5), 538–540 (2013).
   PubMed Web of Science ®Google Scholar
• Frodyma D , NeilsenB, Costanzo-GarveyD, FisherK, LewisR. Coordinating ERK signaling via the molecular scaffold Kinase Suppressor of Ras. F1000Res6, 1621 (2017).
   PubMedGoogle Scholar
• Jang H , StevensP, GaoT, GalperinE. The leucine-rich repeat signaling scaffolds Shoc2 and Erbin: cellular mechanism and role in disease. FEBS J288(3), 721–739 (2021).
   PubMed Web of Science ®Google Scholar
• Jones GG , DelRio IB, SariSet al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat. Commun.10(1), 2532 (2019).
   PubMedGoogle Scholar
• Geng W , DongK, PuQ, LvY, GaoH. SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer. Mol. Med. Rep.21(2), 867–875 (2020).
   PubMed Web of Science ®Google Scholar
• Ji P , DiederichsS, WangWet al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene22(39), 8031–8041 (2003).
   PubMed Web of Science ®Google Scholar
• Qiao FH , TuM, LiuHY. Role of MALAT1 in gynecological cancers: pathologic and therapeutic aspects. Oncol. Lett.21(4), 333 (2021).
   PubMed Web of Science ®Google Scholar
• Yoshimoto R , MayedaA, YoshidaM, NakagawaS. MALAT1 long non-coding RNA in cancer. Biochim. Biophys. Acta1859(1), 192–199 (2016).
   PubMed Web of Science ®Google Scholar
• Arun G , SpectorDL. MALAT1 long non-coding RNA and breast cancer. RNA Biol.16(6), 860–863 (2019).
   PubMed Web of Science ®Google Scholar
• Huang XJ , XiaY, HeGFet al. MALAT1 promotes angiogenesis of breast cancer. Oncol. Rep.40(5), 2683–2689 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Z , WangX, ZhangTet al. lncRNA MALAT1 promotes gastric cancer progression via inhibiting autophagic flux and inducing fibroblast activation. Cell Death Dis.12(4), 368 (2021).
   PubMed Web of Science ®Google Scholar
• Jadaliha M , ZongX, MalakarPet al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget7(26), 40418–40436 (2016).
   PubMedGoogle Scholar
• Liu J , ZhouY, ShiZet al. microRNA-497 modulates breast cancer cell proliferation, invasion, and survival by targeting SMAD7. DNA Cell Biol.35(9), 521–529 (2016).
   PubMed Web of Science ®Google Scholar
• Ma Y , YanJ, QiH, MaL. Effects of miR-497-5p on proliferation and apoptosis of paclitaxel resistant breast cancer cells. Chin. J. Clin. Pharmacol.37(20), 2763–2765,2769 (2021).
   Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Invitrogen . Lipofectamine® product information sheet. http://tools.thermofisher.com/content/sfs/manuals/Lipofectamine_2000_Reag_protocol.pdf
   Google Scholar
• Li JH , LiuS, ZhouH, QULH, YangJH.:starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.Nucleic Acids Res42(Database issue), D92–97 (2014)
   PubMed Web of Science ®Google Scholar
• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Ataollahi MR , SharifiJ, PaknahadMR, PaknahadA. Breast cancer and associated factors: a review. J. Med. Life8(Spec Iss 4), 6–11 (2015).
   PubMedGoogle Scholar
• Lukasiewicz S , CzeczelewskiM, FormaA, BajJ, SitarzR, StanislawekA. Breast cancer – epidemiology, risk factors, classification, prognostic markers, and current treatment strategies – an updated review. Cancers (Basel)13(17), 4287 (2021).
   PubMed Web of Science ®Google Scholar
• Gote V , NookalaAR, BollaPK, PalD. Drug resistance in metastatic breast cancer: tumor targeted nanomedicine to the rescue. Int. J. Mol. Sci.22(9), 4673 (2021).
   PubMed Web of Science ®Google Scholar
• Othman A , WinogradzkiM, LeeL, TandonM, BlankA, PratapJ. Bone metastatic breast cancer: advances in cell signaling and autophagy related mechanisms. Cancers (Basel)13(17), 4310 (2021).
   PubMed Web of Science ®Google Scholar
• ENCODE Project Consortium , BirneyE, StamatoyannopoulosJAet al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature447(7146), 799–816 (2007).
   PubMed Web of Science ®Google Scholar
• Kazimierczyk M , KasprowiczMK, KasprzykME, WrzesinskiJ. Human long noncoding RNA interactome: detection, characterization and function. Int. J. Mol. Sci.21(3), 1027 (2020).
   PubMed Web of Science ®Google Scholar
• Tsai MC , SpitaleRC, ChangHY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res.71(1), 3–7 (2011).
   PubMed Web of Science ®Google Scholar
• Fu S , WangY, LiH, ChenL, LiuQ. Regulatory networks of lncRNA MALAT-1 in cancer. Cancer Manag. Res.12, 10181–10198 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang X , HamblinMH, YinKJ. The long noncoding RNA MALAT1: its physiological and pathophysiological functions. RNA Biol.14(12), 1705–1714 (2017).
   PubMed Web of Science ®Google Scholar
• Kim J , PiaoHL, KimBJet al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat. Genet.50(12), 1705–1715 (2018).
   PubMed Web of Science ®Google Scholar
• Wang N , CaoS, WangX, ZhangL, YuanH, MaX. lncRNA MALAT1/miR26a/26b/ST8SIA4 axis mediates cell invasion and migration in breast cancer cell lines. Oncol Rep46(2), 181 (2021).
   PubMed Web of Science ®Google Scholar
• Ren S , LiuY, XuWet al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol.190(6), 2278–2287 (2013).
   PubMed Web of Science ®Google Scholar
• Liu C , HanX, LiBet al. MALAT-1 is associated with the doxorubicin resistance in U-2OS osteosarcoma cells. Cancer Manag. Res.13, 6879–6889 (2021).
   PubMed Web of Science ®Google Scholar
• Chen D , XuT, ChangHHet al. The role of MALAT1 in cancer. J. Cancer Sci. Clin. Ther.3, 5–27 (2019).
   Google Scholar
• Yang G , XiongG, CaoZet al. miR-497 expression, function and clinical application in cancer. Oncotarget7(34), 55900–55911 (2016).
   PubMedGoogle Scholar
• Hou Z , WangY, XiaN, LvT, YuanX, SongY. Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR. Cancer Sci112(1), 275–286 (2021).
   PubMed Web of Science ®Google Scholar
• Wassarman DA , TherrienM, RubinGM . The Ras signaling pathway in Drosophila. Curr Opin Genet Dev5(1), 44–50 (2016).
   Google Scholar
• Lavoie H , TherrienM.Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol16(5), 281–298 (2015).
   PubMed Web of Science ®Google Scholar
• Huang C , ZhangX, JiangL, ZhangL, XiangM, RenH. FoxM1 induced paclitaxel resistance via activation of the FoxM1/PHB1/RAF–MEK–ERK pathway and enhancement of the ABCA2 transporter. Mol. Ther. Oncolytics14, 196–212 (2019).
   PubMed Web of Science ®Google Scholar
• Jeoung M , JangER, LiuJet al. Shoc2-tranduced ERK1/2 motility signals – novel insights from functional genomics. Cell. Signal.28(5), 448–459 (2016).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P , Oses-PrietoJ, BurlingameA, FriedM, McCormickF. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol. Cell22(2), 217–230 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan FM , KugelCH3rd, DadpeyN, ShaoY, AbelEV, AplinAE. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J. Biol. Chem.287(50), 41797–41807 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao S , QiuZX, ZhangL, LiWM.Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer. Tumour Biol36(6), 4143–4150 (2015).
   PubMedGoogle Scholar
• Stampolidis P , UllrichA, IacobelliS. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. Oncogene.34(1), 39–52 (2015).
   PubMed Web of Science ®Google Scholar